75051-55-7

Basic information

• Product Name: Carbamic acid, [2-(aminooxy)ethyl]-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, [2-(aminooxy)ethyl]-, 1,1-dimethylethyl ester (9CI);tert-butyl 2-(aminooxy)ethylcarbamate;(2-Aminooxyethyl)carbamic acid tert-butyl ester;Carbamic acid, [2-(aminooxy)ethyl]-, 1,1-dimethylethyl ester;tert-butyl N-[2-(aminooxy)ethyl]carbamate
• CAS NO: 75051-55-7
• Molecular Formula: C₇H₁₆N₂O₃
• Molecular Weight: 176.21354
• Product Categories: N-BOC
• Mol File: 75051-55-7.mol

Chemical Properties

• Boiling Point: 303.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.058±0.06 g/cm3(Predicted)
• PKA: 12.57±0.46(Predicted)
• CAS DataBase Reference: Carbamic acid, [2-(aminooxy)ethyl]-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [2-(aminooxy)ethyl]-, 1,1-dimethylethyl ester (9CI)(75051-55-7)
• EPA Substance Registry System: Carbamic acid, [2-(aminooxy)ethyl]-, 1,1-dimethylethyl ester (9CI)(75051-55-7)

Safety Data

• Hazardous Substances Data: 75051-55-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Carbamic acid, [2-(aminooxy)ethyl]-, 1,1-dimethylethyl ester (9CI) is used as a reagent for the protection of amines in organic synthesis. It is particularly useful for the selective protection of amines in the presence of other functional groups, making it a valuable tool in the development of complex organic molecules.
Used in Peptide Synthesis:
In the field of peptide synthesis, Carbamic acid, [2-(aminooxy)ethyl]-, 1,1-dimethylethyl ester (9CI) is used as a reagent for the protection of amines. This selective protection allows for the synthesis of complex peptide structures without unwanted side reactions, facilitating the development of novel therapeutic agents and other bioactive compounds.
It is important to handle and use Carbamic acid, [2-(aminooxy)ethyl]-, 1,1-dimethylethyl ester (9CI) with caution, as it can be hazardous if not properly managed.

Upstream product

• 87276-51-5 [2-(1,3-dioxo-1,3-dihydroisoindol-2-yloxy)-ethyl]carbamic acid tert-butyl ester 
• 60-34-4 methylhydrazine 
• 39684-80-5 2-(tert-butoxycarbonylamino)ethyl bromide 
• 26690-80-2 2-(N-tert-butoxycarbonylamino)ethanol 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1596369-01-5 N-(2-aminoethoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide 
• 1452466-19-1 {2-[({[(2S,5R)-6-benzyloxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}amino)oxy]ethyl}carbamic acid tert-butyl ester 
• 1007552-74-0 C₂₃H₂₃BrF₃N₃O₄S₂ 

Relevant articles and documents

Discovery of a Tricyclic β-Lactam as a Potent Antimicrobial Agent against Carbapenem-Resistant Enterobacterales, Including Strains with Reduced Membrane Permeability and Four-Amino Acid Insertion into Penicillin-Binding Protein 3: Structure-Activity-Relationships and In Vitro and In Vivo Activities

The current worldwide emergence of carbapenem-resistant enterobacterales (CREs) constitutes an important growing clinical and public health threat. Acquired carbapenemases are the most important determinants of resistance to carbapenems. In the development of the previously reported tricyclic β-lactam skeleton which exhibits potent antibacterial activities against several problematic β-lactamase-producing CREs without a β-lactamase inhibitor, we found that these activities were reduced against clinical isolates with resistance mechanisms other than β-lactamase production. These mechanisms were the reduction of outer membrane permeability with the production of β-lactamases and the insertion of four amino acids into penicillin-binding protein 3. Here, we report the discovery of a potent compound that overcomes these resistance mechanisms by the conversion of the alkoxyimino moiety of the aminothiazole side chain in which a hydrophilic functional group is introduced and the carboxylic acid of the alkoxyimino moiety is converted to reduce the negative charge of the whole molecule from 2 to 1. This potent tricyclic β-lactam is a promising drug candidate for infectious diseases caused by CREs due to its potent therapeutic efficacy in the neutropenic mouse lung infection model and low frequency of producing spontaneously resistant mutants.

Diazabicyclo compounds and application thereof

The invention belongs to the field of medical chemistry and, relates to diazabicyclo compounds and application thereof, and particularly provides compounds as shown in the formula (I) or isomers, pharmaceutically acceptable salts, solvates, crystals or pr

1,2,5-oxadiazole derivative used as indoleamine 2,3-dioxygenase inhibitor

The invention belongs to the technical field of 1,2,5-oxadiazole derivatives, and particularly relates to a 1,2,5-oxadiazole derivative or a pharmaceutically acceptable salt thereof which is used as an indoleamine 2,3-dioxygenase inhibitor. The structure of the 1,2,5-oxadiazole derivative or the pharmaceutically acceptable salt thereof used as the IDO inhibitor is shown in the following formula I.The invention provides a general formula compound I with a novel structure. Experimental results show that some compounds have excellent IDO inhibitory activity and permeation performance at the sametime. The compound is expected to be marketed as a tumor molecular immunotherapeutic drug for cancer treatment.

Beta-lactamase inhibitors and uses thereof

β-Lactamase inhibiting compounds, therapeutic methods of using the β-lactamase inhibiting compounds, particularly in combination with β-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The β-lactamase inhibiting compounds are suitable for oral administration.

With tumor homing therapeutic polypeptide - drug conjugates and application thereof (by machine translation)

The present invention relates to guide treatment with tumor polypeptide - drug conjugates, polypeptide - drug conjugates preparation method and its application. The polypeptide of the invention - drug conjugates can be specific will PD0325901 analogs to d

The synthesis and BK channel-opening activity of N-acylaminoalkyloxime derivatives of dehydroabietic acid

A series of N-acylaminoalkyloxime derivatives of dehydroabietic acid were synthesized and evaluated for BK channel-opening activities in an assay system of CHO-K1 cells expressing hBKα channels. The structure-activity relationship study revealed that a non-covalent interaction between the S atom of the 2-thiophene and the carbonyl O atom may contribute to conformation restriction for interaction with the ion channel. This research could guide the design and synthesis of novel abietane-based BK channel opener.

A PROCESS FOR PREPARATION OF (2S, 5R)-N-(2-AMINO ETHOXY)-6-(SULFOOXY)-7-OXO-1,6- DIAZABICYCLO [3.2.1] OCTANE-2-CARBOXAMIDE

A process for preparation of (2S,5R)-N-(2-aminoethoxy)-6-(sulfooxy)-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carboxamide is disclosed. Formula (I)

NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME

The currently available β-lactamase inhibitors are insufficient to inhibit the incessantly increasing β-lactamase, and novel β-lactamase inhibitors has been required today for the difficult treatment for bacterial infectious diseases caused by resistant bacteria which produce class C β-lactamase, extended-spectrum β-lactamase (ESBL) belonging to class A and D, or class A KPC-2 decomposing even carbapenem as a last resort for β-lactam antibiotic. A compound represented by the the formula (I), preparation process of the same, β-lactamase inhibitors and method for treating bacterial infectious diseases are provided.

Synthesis and biological evaluation of RGD-Conjugated MEK1/2 kinase inhibitors for integrin-targeted cancer therapy

Two novel series of RGD-MEKI conjugates derived from a MEK1/2 kinase inhibitor-PD0325901-have been developed for integrin receptor mediated anticancer therapy. The first series, alkoxylamine analog RGD-MEKI conjugates 9a-g showed anti-proliferation activity in melanoma A375 cells by the same mechanism as that of PD0325901. PEGylation increased the IC50 value of 9f three-fold in the A375 assay, and the multi-cRGD peptide cargo significantly improved the receptor specific anti-proliferation activity of 9g in integrin-overexpressing U87 cells. In the second series, RGD-PD0325901 13 exhibited significantly increased antitumor properties compared to the alkoxylamine analogs by both inhibition of the ERK pathway activity and DNA replication of the cancer cells. Furthermore, 13 displayed more potent anti-proliferation activity in the U87 assay than PD0325901 in a dose-dependent manner. All these data demonstrate that RGD-MEKI conjugates with an ester bond linkage enhanced anticancer efficacy with improved targeting capability toward integrin-overexpressing tumor cells.

OXIM DERIVATIVES AS HSP90 INHIBITORS

The invention relates to HSP90 inhibiting compounds consisting of the formula: (I) wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.